AIM: To assess the prognostic significance of cathepsin L, a cysteine protease that degrades the peri-tumoral tissue, in patients with pancreatic cancer. METHODS: Plasma samples from 127 pancreatic cancer patients were analyzed for cathepsin L levels by ELISA. Out of these patients, 25 underwent surgery and their paraffin-embedded tissue was analyzed for cathepsin L expression by immunohistochemistry. Survival of patients and clinicopathological parameters was correlated with cathepsin L expression in plasma and tissue using appropriate statistical analysis. RESULTS: The mean (± SD) cathepsin L in plasma samples of pancreatic cancer patients was 5.98 ± 2.5 ng/mL that was significantly higher compared to the levels in healthy controls (3.83 ± 0.45) or chronic pancreatitis patients (3.97 ± 1.06). Using ROC curve, a cut-off level of 5.0 ng/mL was decided for survival analysis. Elevated plasma levels of cathepsin L were found to be associated with poor prognosis (P = 0.01) in multivariate analysis. The plasma levels of the protease decreased after surgery. Though no significant correlation was seen between plasma and tissue expression of this protease, a trend did emerge that high cathepsin L expression in tissue correlated with its high levels in plasma. CONCLUSION: Cathepsin L levels in plasma of pancreatic cancer patients may be used as a potential prognostic marker for the disease.
AIM: To assess the prognostic significance of cathepsin L, a cysteine protease that degrades the peri-tumoral tissue, in patients with pancreatic cancer. METHODS: Plasma samples from 127 pancreatic cancerpatients were analyzed for cathepsin L levels by ELISA. Out of these patients, 25 underwent surgery and their paraffin-embedded tissue was analyzed for cathepsin L expression by immunohistochemistry. Survival of patients and clinicopathological parameters was correlated with cathepsin L expression in plasma and tissue using appropriate statistical analysis. RESULTS: The mean (± SD) cathepsin L in plasma samples of pancreatic cancerpatients was 5.98 ± 2.5 ng/mL that was significantly higher compared to the levels in healthy controls (3.83 ± 0.45) or chronic pancreatitispatients (3.97 ± 1.06). Using ROC curve, a cut-off level of 5.0 ng/mL was decided for survival analysis. Elevated plasma levels of cathepsin L were found to be associated with poor prognosis (P = 0.01) in multivariate analysis. The plasma levels of the protease decreased after surgery. Though no significant correlation was seen between plasma and tissue expression of this protease, a trend did emerge that high cathepsin L expression in tissue correlated with its high levels in plasma. CONCLUSION:Cathepsin L levels in plasma of pancreatic cancerpatients may be used as a potential prognostic marker for the disease.
Entities:
Keywords:
Cathepsin L; Overall median survival; Pancreatic cancer; Plasma
Authors: John Collette; Jeffrey P Bocock; Kyujeong Ahn; Richard L Chapman; Gene Godbold; Susan Yeyeodu; Ann Hart Erickson Journal: Int Rev Cytol Date: 2004
Authors: T T Lah; M Kokalj-Kunovar; B Strukelj; J Pungercar; D Barlic-Maganja; M Drobnic-Kosorok; L Kastelic; J Babnik; R Golouh; V Turk Journal: Int J Cancer Date: 1992-01-02 Impact factor: 7.396
Authors: Jacqueline M Lankelma; Daniëlle M Voorend; Temo Barwari; Joris Koetsveld; Anne H Van der Spek; Alexander P N A De Porto; Geeske Van Rooijen; Cornelis J F Van Noorden Journal: Life Sci Date: 2009-11-30 Impact factor: 5.037
Authors: M Sivaparvathi; M Yamamoto; G L Nicolson; Z L Gokaslan; G N Fuller; L A Liotta; R Sawaya; J S Rao Journal: Clin Exp Metastasis Date: 1996-01 Impact factor: 5.150
Authors: Kelton A Schleyer; Ben Fetrow; Peter Zannes Fatland; Jun Liu; Maya Chaaban; Biwu Ma; Lina Cui Journal: ChemMedChem Date: 2021-01-15 Impact factor: 3.466
Authors: Caio P Gomes; Danilo E Fernandes; Fernanda Casimiro; Gustavo F da Mata; Michelle T Passos; Patricia Varela; Gianna Mastroianni-Kirsztajn; João Bosco Pesquero Journal: Front Cell Infect Microbiol Date: 2020-12-08 Impact factor: 5.293